NASDAQ:DERM - Dermira Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.61 -0.12 (-1.23 %) (As of 08/17/2018 04:00 PM ET)Previous Close$9.73Today's Range$9.37 - $9.7852-Week Range$6.98 - $31.42Volume269,100 shsAverage Volume1.19 million shsMarket Capitalization$419 millionP/E Ratio-2.16Dividend YieldN/ABeta1.47 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California. Receive DERM News and Ratings via Email Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:DERM CUSIPN/A Webwww.dermira.com Phone650-421-7200 Debt Debt-to-Equity Ratio2.49 Current Ratio4.78 Quick Ratio4.78 Price-To-Earnings Trailing P/E Ratio-2.16 Forward P/E Ratio-1.86 P/E GrowthN/A Sales & Book Value Annual Sales$4.54 million Price / Sales88.97 Cash FlowN/A Price / CashN/A Book Value$3.59 per share Price / Book2.68 Profitability EPS (Most Recent Fiscal Year)($4.39) Net Income$-303,260,000.00 Net Margins-761.87% Return on Equity-128.21% Return on Assets-33.87% Miscellaneous Employees162 Outstanding Shares42,030,000Market Cap$419 million Dermira (NASDAQ:DERM) Frequently Asked Questions What is Dermira's stock symbol? Dermira trades on the NASDAQ under the ticker symbol "DERM." How were Dermira's earnings last quarter? Dermira Inc (NASDAQ:DERM) released its quarterly earnings data on Monday, August, 6th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.57). The biopharmaceutical company earned $39.08 million during the quarter, compared to analyst estimates of $39 million. Dermira had a negative return on equity of 128.21% and a negative net margin of 761.87%. View Dermira's Earnings History. When is Dermira's next earnings date? Dermira is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Dermira. What price target have analysts set for DERM? 6 analysts have issued 1-year price targets for Dermira's stock. Their forecasts range from $16.00 to $48.00. On average, they expect Dermira's stock price to reach $29.6667 in the next year. This suggests a possible upside of 208.7% from the stock's current price. View Analyst Price Targets for Dermira. What is the consensus analysts' recommendation for Dermira? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira. What are Wall Street analysts saying about Dermira stock? Here are some recent quotes from research analysts about Dermira stock: 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (8/13/2018) 2. Cantor Fitzgerald analysts commented, "We remain positive on DERM’s stock following a group investor dinner we held on 3/26/18 with COO & CFO Andrew Guggenhime and VP of IR Ian Clements." (3/27/2018) Who are some of Dermira's key competitors? Some companies that are related to Dermira include Aimmune Therapeutics (AIMT), Allakos (ALLK), Theravance Biopharma (TBPH), Corcept Therapeutics (CORT), ARMO Biosciences (ARMO), Amneal Pharmaceuticals (AMRX), Arrowhead Pharmaceuticals (ARWR), TESARO (TSRO), Myovant Sciences (MYOV), IMMURON Ltd/S (IMRN), Innoviva (INVA), Impax Laboratories (IPXL), Deciphera Pharmaceuticals (DCPH), ImmunoGen (IMGN) and Alder Biopharmaceuticals (ALDR). Who are Dermira's key executives? Dermira's management team includes the folowing people: Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 66)Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 76)Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 50)Mr. Luis C. Peña, Chief Devel. Officer (Age 55)Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 41) Has Dermira been receiving favorable news coverage? News coverage about DERM stock has trended somewhat positive on Friday, according to Accern Sentiment. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dermira earned a news and rumor sentiment score of 0.02 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 47.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Dermira. Who are Dermira's major shareholders? Dermira's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Voya Investment Management LLC (2.85%), Orbimed Advisors LLC (2.45%), Dimensional Fund Advisors LP (1.48%), C WorldWide Group Holding A S (1.15%), First Midwest Bank Trust Division (0.78%) and Schwab Charles Investment Management Inc. (0.41%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira. Which major investors are selling Dermira stock? DERM stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, BlueMountain Capital Management LLC, NumerixS Investment Technologies Inc, Cubist Systematic Strategies LLC and Fox Run Management L.L.C.. Company insiders that have sold Dermira company stock in the last year include Christopher M Griffith, David E Cohen, Eugene A Bauer and Thomas G Wiggans. View Insider Buying and Selling for Dermira. Which major investors are buying Dermira stock? DERM stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, C WorldWide Group Holding A S, Dimensional Fund Advisors LP, Los Angeles Capital Management & Equity Research Inc., First Midwest Bank Trust Division, Engineers Gate Manager LP, Voya Investment Management LLC and Tibra Equities Europe Ltd. Company insiders that have bought Dermira stock in the last two years include Fred B Craves and Thomas G Wiggans. View Insider Buying and Selling for Dermira. How do I buy shares of Dermira? Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Dermira's stock price today? One share of DERM stock can currently be purchased for approximately $9.61. How big of a company is Dermira? Dermira has a market capitalization of $419 million and generates $4.54 million in revenue each year. The biopharmaceutical company earns $-303,260,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. Dermira employs 162 workers across the globe. How can I contact Dermira? Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected] MarketBeat Community Rating for Dermira (NASDAQ DERM)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 217 (Vote Outperform)Underperform Votes: 193 (Vote Underperform)Total Votes: 410MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/17/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?